VolitionRx Reports Full Fiscal Year 2025 Financial Results and Business Update, Anticipates Further Human Licensing Deals.

VolitionRx Limited announces FY25 financial results, with full-year revenue of $1.7 million, a 40% increase from the previous year. Q4 revenue grew 133% YoY. Operating expenses were down 17% compared to last year, and net loss decreased 14%. The company received $5.4 million in net proceeds from equity sales, $1.9 million from a convertible note, and $1 million from non-dilutive funding from the Walloon Region.